Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
KO
Kodiak Sciences Inc Common Stock
KOD
Mkt Cap
$5.39B
Volume
956.35K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
KO
KOD
KO
Kodiak Sciences Inc Common Stock
KOD
News
·
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
Mkt Cap
$5.54B
Volume
956.35K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Insider
Filings
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
Kodiak Sciences announced positive Phase III DAYBREAK study results for Zenkuda (tarcocimab tedromer), showing non-inferiority to Regeneron's Eylea in treating wet age-related macular degeneration. The drug demonstrated sustained retinal drying with 54% of patients reaching a six-month dosing interval, superior safety profile, and strong durability. Kodiak plans a multi-indication BLA submission in Q4 2026. The stock surged 178% on the announcement.
Zacks Investment Research · Sep 29, 2026
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte
Four biotech companies—Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics, and Vaxcyte—are approaching significant clinical trial readouts in fall 2026 that could materially impact their valuations. Kodiak will report phase III data for wet AMD treatments, Celldex expects CSU study results, Rapport targets bipolar mania trial outcomes, and Vaxcyte will release pneumococcal vaccine data. These mid- to late-stage readouts represent major catalysts for clinical-stage companies.
Zacks Investment Research · Sep 23, 2026
Diabetic Retinopathy Pipeline Insight 2026: Comprehensive Analysis of 50+ Companies and 55+ Drugs in Development
A comprehensive pipeline analysis reveals over 50 companies developing 55+ drugs for diabetic retinopathy treatment. Key developments include Kodiak Sciences' Tarcocimab tedromer (Phase III anti-VEGF therapy), Vantage Biosciences' VX-01 (Phase II oral treatment), and Therini Bio's THN391 (Phase I fibrin-targeting therapy). The report covers therapeutic assessments across various development stages, routes of administration, and molecule types, highlighting emerging opportunities in retinal disease treatment.
GlobeNewswire Inc. · Jul 3, 2026
Russell 2000 Rips To Record High — Here Are The Top Small Cap Gainers
The Russell 2000 small-cap index reached an intraday record high on Friday, capping a 13-day rally—its best run since 2020. The surge was driven by President Trump's announcement of a two-week military pause against Iran, which lowered oil prices and boosted expectations for Federal Reserve rate cuts. Regional banks, industrials, and biotech stocks have led the gains, with the iShares Russell 2000 ETF up 8.6% over two weeks compared to the S&P 500's 1.6% gain.
Benzinga · Apr 17, 2026
Ameresco, Lithium Americas, Kodiak Sciences And Other Big Stocks Moving Higher On Thursday
Several stocks saw significant gains on Thursday, with Ameresco receiving a bullish upgrade from Jefferies, Lithium Americas experiencing potential government interest, and Kodiak Sciences getting an analyst upgrade.
Benzinga · Sep 25, 2025
Diabetic Retinopathy Global Clinical Trials Review 2024: Region, country (G7 & E7), phase, trial status, End-points Status and Sponsor Type
The report provides an overview of the global clinical trials landscape for diabetic retinopathy, including details on trial numbers, enrollment, and status across different regions, countries, phases, and sponsor types. It also highlights prominent drugs and companies involved in these trials.
GlobeNewswire Inc. · Jan 10, 2025
Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?
Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.
Zacks Investment Research · Jun 20, 2024
Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report?
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks Investment Research · Jun 14, 2024
Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
Kodiak (KOD) reports better-than-expected first-quarter 2024 results and provides updates regarding its pipeline development plans.
Zacks Investment Research · May 16, 2024
Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks
Kodiak (KOD) initiates a phase III study evaluating tarcocimab in diabetic retinopathy, which is expected to serve as the basis for a regulatory filing for three eye disease indications.
Zacks Investment Research · Apr 4, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
KO
KOD
Kodiak Sciences Inc Common Stock
Buy
Sell
Market
Limit
Soon
KOD
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any KOD yet.
Related Tickers
Earnings